METHODS OF COST-EFFECTIVENESS ANALYSIS - AREAS OF CONSENSUS AND DEBATE

被引:44
作者
LUCE, BR
SIMPSON, K
机构
[1] Battelle Medical Technology Assessment and Policy (MEDTAP) Research Center, Arlington, VA
关键词
D O I
10.1016/0149-2918(95)80012-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Methods of evaluating socioeconomic relationships have evolved over many years, and a number of specific approaches have been developed. Among the techniques available, cost-effectiveness analysis (CEA) has emerged as the most widely used and accepted method. Yet, despite considerable effort by the analytical community to refine this technique into one more useful for making health policy decisions, much debate and confusion still persist among analysts, readers, and policymakers concerning methods standards and the overall usefulness of CEA in resource allocation decision making. Thus the purpose of this paper is to summarize, critically examine, and comment on existing recommended methods for socioeconomic evaluation of health care interventions. In particular, we examine an exhaustive set of component methods within the general area of cost-effectiveness and comment on areas of apparent consensus and debate. Our review reveals many areas of agreement and many yet to be resolved. Analysts generally agree on the components of the overall framework for an analysis; basic methodologic principles; the general treatment of costs; the principle of marginal analysis; the need for and general approach to discounting; the use of sensitivity analysis; the extent to which ethical issues can be incorporated; and the importance of choosing appropriate alternatives for comparison. The principal areas in which disagreement still persists are choice of study design, measurement and valuation of health outcomes including conversion of health outcomes to economic values, transformation of efficacy results into effectiveness outcomes, and the empirical measurement of costs.
引用
收藏
页码:109 / 125
页数:17
相关论文
共 69 条
  • [1] Kamlet, A Framework for Cost-Utility Analysis of Government Health Care Programs: The Comparative Benefits Modeling Project, (1992)
  • [2] Steiner, Public expenditure budgeting, The Economics of Public Financing. Studies of Government and Finance, pp. 241-360, (1974)
  • [3] Elixhauser, Luce, Cost-benefit and cost-effectiveness analysis from 1979 to 1990: A bibliography, Med Care, 31, pp. S1-S11, (1993)
  • [4] Drummond, Current concerns about economic evaluation, Pharm Times, 10, pp. 18-19, (1990)
  • [5] Drummond, Brandt, Luce, Rovira, Standardizing economic evaluation methodologies in health care, Int J Technol Assess Health Care, 9, pp. 26-36, (1993)
  • [6] Hillman, Eisenberg, Pauly, Et al., Sounding board: Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies, NEJM, 324, pp. 1362-1365, (1991)
  • [7] Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: Including submissions involving economic analysis, (1990)
  • [8] Henry, Economic analysis as an aid to subsidization decisions: The development of Australian guidelines for pharmaceuticals, PharmacoEconomics, 1, pp. 54-67, (1992)
  • [9] Canadian Coordinating Office for Health Technology Assessment, Guidelines for Economic Evaluation of Pharmaceuticals: Canada, (1994)
  • [10] Memorandum: “Status Report on Ontario's Draft Guidelines for Economic Analysis of Drugs”